We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
19.39 | 2.07% | 957.00 | 954.85 | 990.00 | 958.13 | 926.94 | 926.94 | 547,374 | 05:00:06 |
1. Name and Address of Reporting Person * Landry Robert E | 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Finance CFO |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 6/8/2020 | M(1) | 3500 | A | $272.7 | 27873 | D | |||
Common Stock | 6/8/2020 | F(1) | 2536 | D | $592.43 | 25337 | D | |||
Common Stock | 6/8/2020 | M(1) | 3500 | A | $272.7 | 28837 | D | |||
Common Stock | 6/8/2020 | F(1) | 2536 | D | $592.43 | 26301 | D | |||
Common Stock | 6/8/2020 | M(1) | 2500 | A | $272.7 | 28801 | D | |||
Common Stock | 6/8/2020 | F(1) | 1811 | D | $592.4 | 26990 | D | |||
Common Stock | 6/8/2020 | M(1) | 2250 | A | $272.7 | 29240 | D | |||
Common Stock | 6/8/2020 | F(1) | 1630 | D | $592.43 | 27610 | D | |||
Common Stock | 6/8/2020 | M(1) | 2250 | A | $272.7 | 29860 | D | |||
Common Stock | 6/8/2020 | F(1) | 1630 | D | $592.43 | 28230 | D | |||
Common Stock | 6/8/2020 | M(1) | 1500 | A | $272.7 | 29730 | D | |||
Common Stock | 6/8/2020 | F(1) | 1086 | D | $592.43 | 28644 | D | |||
Common Stock | 6/9/2020 | S(1) | 110 | D | $602.38 (2) | 28534 | D | |||
Common Stock | 6/9/2020 | S(1) | 131 | D | $603.68 (3) | 28403 | D | |||
Common Stock | 6/9/2020 | S(1) | 50 | D | $604.14 | 28353 | D | |||
Common Stock | 6/9/2020 | S(1) | 289 | D | $605.14 (4) | 28064 | D | |||
Common Stock | 6/9/2020 | S(1) | 353 | D | $606.79 (5) | 27711 | D | |||
Common Stock | 6/9/2020 | S(1) | 619 | D | $607.47 (6) | 27092 | D | |||
Common Stock | 6/9/2020 | S(1) | 1511 | D | $608.5 (7) | 25581 | D | |||
Common Stock | 6/9/2020 | S(1) | 681 | D | $609.53 (8) | 24900 | D | |||
Common Stock | 6/9/2020 | S(1) | 527 | D | $610.25 (9) | 24373 | D | |||
Common Stock | 200 | I | By 401(k) Plan |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | M (1) | 3500 | (10) | 9/9/2023 | Common Stock | 3500 | $0.0 | 15500 | D | ||||
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | M (1) | 3500 | (10) | 9/9/2023 | Common Stock | 3500 | $0.0 | 12000 | D | ||||
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | M (1) | 2500 | (10) | 9/9/2023 | Common Stock | 2500 | $0.0 | 9500 | D | ||||
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | M (1) | 2250 | (10) | 9/9/2023 | Common Stock | 2250 | $0.0 | 7250 | D | ||||
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | M (1) | 2250 | (10) | 9/9/2023 | Common Stock | 2250 | $0.0 | 5000 | D | ||||
Non-Qualified Stock Option (right to buy) | $272.7 | 6/8/2020 | M (1) | 1500 | (10) | 9/9/2023 | Common Stock | 1500 | $0.0 | 3500 | D |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Landry Robert E 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 | EVP Finance CFO |
Signatures | ||
/s/**Robert E. Landry | 6/10/2020 | |
**Signature of Reporting Person | Date |
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions